Trials / Recruiting
RecruitingNCT06541314
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
A Multicenter, Single-Arm Clinical Study of Fluzoparib Monotherapy As Neoadjuvant Treatment for Advanced Epithelial Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV , BRCA mutations or HRD positive epithelial ovarian cancer who cannot achieve R0 surgery as assessed by imaging (Suidan's CT score) or laparoscopy (Fagotti score), or cannot tolerate surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total. |
Timeline
- Start date
- 2024-06-18
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
- First posted
- 2024-08-07
- Last updated
- 2024-11-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06541314. Inclusion in this directory is not an endorsement.